ATLANTA—Aveanna Healthcare Holdings Inc., a homecare platform focused on providing care to medically complex, high-cost patient populations, announced financial results for its 2026 first quarter (Q1), ended April 4, 2026.
“Q1 reflects the strength and resiliency of our business model with an impressive start to 2026," said Jeff Shaner, CEO. "Our first quarter results saw revenue and adjusted EBITDA increase 15.9% and 25.2%, respectively, when compared to the prior year period, and our guidance has been revised to reflect the positive momentum we see in 2026."
Aveanna reported revenue was $647.9 million for Q1, as compared to $559.2 million for the same period in 2025, an increase of $88.7 million, or 15.9%. The overall increase in revenue was attributable to a $75.7 million increase in private duty services (PDS) segment revenue, a $9.9 million increase in home health and hospice segment revenue and a $3.2 million increase in medical solutions segment revenue compared to the first quarter in 2025.
Gross margin was $205.4 million, or 31.7% of revenue, in Q1, compared to $183.6 million, or 32.8% of revenue, in 2025, an increase of $21.9 million, or 11.9%.
In Q1 2026, net income was $41.7 million compared to Q1 2025, with a net income of $5.2 million. Net income per diluted share was $0.19 versus a net income per diluted share of $0.03 in 2025. Adjusted net income in 2026 per diluted share was $0.18, up from $0.10 in 2025.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was $84.4 million, or 13% of revenue, for the first quarter, as compared to $67.4 million, or 12% of revenue, in Q1 2025, an increase of $17 million or 25.2%.
“We are pleased with our strong start to 2026," said Matt Buckhalter, chief financial officer for Aveanna. "Our team continued to execute at a high level across all three divisions. For the first quarter, we delivered revenue of $647.9 million, representing growth of 15.9%, and adjusted EBITDA of $84.4 million, representing growth of 25.2%. These results underscore the resilience of our care model and the ongoing commitment of our caregivers in delivering high quality services to our patients. Consistent with our standard practice, our full-year 2026 guidance excludes the pending acquisition. Our raised guidance for 2026 of revenue between $2.56 and $2.58 billion and adjusted EBITDA between $328 and $332 million is a testament to the outstanding efforts put forth by our clinicians and operators.”